Anetumab ravtansine, an anti-MSLN ADC, showed an ORR of 27.7% and a median PFS of 5 months in combination with pegylated liposomal doxorubicin in a phase Ib study (NCT02751918) in patients with platinum-resistant epithelial ovarian cancer [119]. Here, MSLN is linked to ovarian carcinoma.